Familial forms of focal segmental glomerulosclerosis (FSGS) have been linked to gain-of-function mutations in the gene encoding the transient receptor potential channel C6 (TRPC6). GPCRs coupled to Gq signaling activate TRPC6, suggesting that Gq-dependent TRPC6 activation underlies glomerular diseases. Here, we developed a murine model in which a constitutively active Gq α subunit (GqQ209L, referred to herein as GqQ>L) is specifically expressed in podocytes and examined the effects of this mutation in response to puromycin aminonucleoside (PAN) nephrosis. We found that compared with control animals, animals expressing GqQ>L exhibited robust albuminuria, structural features of FSGS, and reduced numbers of glomerular podocytes. Gq activation stimulated calcineurin (CN) activity, resulting in CN-dependent upregulation of TRPC6 in murine kidneys. Deletion of TRPC6 in GqQ>L-expressing mice prevented FSGS development and inhibited both tubular damage and podocyte loss induced by PAN nephrosis. Similarly, administration of the CN inhibitor FK506 reduced proteinuria and tubular injury but had more modest effects on glomerular pathology and podocyte numbers in animals with constitutive Gq activation. Moreover, these Gq-dependent effects on podocyte injury were generalizable to diabetic kidney disease, as expression of GqQ>L promoted albuminuria, mesangial expansion, and increased glomerular basement membrane width in diabetic mice. Together, these results suggest that targeting Gq/TRPC6 signaling may have therapeutic benefits for the treatment of glomerular diseases.
Familial forms of focal segmental glomerulosclerosis (FSGS) have been linked to gain-of-function mutations in the gene encoding the transient receptor potential channel C6 (TRPC6). GPCRs coupled to Gq signaling activate TRPC6, suggesting that Gq-dependent TRPC6 activation underlies glomerular diseases. Here, we developed a murine model in which a constitutively active Gqα subunit (GqQ209L, referred to herein as GqQ>L) is specifically expressed in podocytes and examined the effects of this mutation in response to puromycin aminonucleoside (PAN) nephrosis. We found that compared with control animals, animals expressing GqQ>L exhibited robust albuminuria, structural features of FSGS, and reduced numbers of glomerular podocytes. Gq activation stimulated calcineurin (CN) activity, resulting in CN-dependent upregulation of TRPC6 in murine kidneys. Deletion of TRPC6 in GqQ>L-expressing mice prevented FSGS development and inhibited both tubular damage and podocyte loss induced by PAN nephrosis. Similarly, administration of the CN inhibitor FK506 reduced proteinuria and tubular injury but had more modest effects on glomerular pathology and podocyte numbers in animals with constitutive Gq activation. Moreover, these Gq-dependent effects on podocyte injury were generalizable to diabetic kidney disease, as expression of GqQ>L promoted albuminuria, mesangial expansion, and increased glomerular basement membrane width in diabetic mice. Together, these results suggest that targeting Gq/TRPC6 signaling may have therapeutic benefits for the treatment of glomerular diseases.

Introduction

GPCRs linked to Gq activation play a key role in glomerular diseases including receptors for angiotensin II (AT1), endothelins (ETA), thromboxanes (TP), cysteinyl-leukotrienes, and E-series prostaglandins (EP1) (1, 2). These cell surface GPCRs are found in podocytes and regulate pathways involved in cell survival, morphology, motility, and cellular attachment (1–6). As a result, GPCRs are important therapeutic targets for the treatment of glomerular disease processes. In this regard, AT1 receptor blockers (ARBs) are extensively used for the treatment of proteinuric kidney diseases (7–9), and combined therapy using ARBs and ETA blockers is currently being evaluated in clinical trials (10–12).

While the pathways activated by these GPCR systems are diverse, these receptors activate Gqα subunits (1). Gq stimulates phospholipase Cβ (PLCβ) and generates the second messengers diacyl glycerol (DAG) and inositol triphosphates (IP3) (1). DAG is a potent activator of PKC (13), and several PKC isoforms play key roles in the pathogenesis of diabetic kidney disease (14). In contrast, IP3 mobilizes calcium from intracellular stores (13), and DAG and possibly inositol phosphates (IPs) promote activation of transient receptor potential channel C6 (TRPC6) in podocytes (1), which further enhances intracellular calcium levels. The importance of calcium in glomerular disease processes is highlighted by the observation that: (a) Gain-of-function mutations in TRPC6 cause familial forms of focal segmental glomerulosclerosis (FSGS) (15, 16), and (b) TRPC6 is upregulated in primary glomerular diseases (17). Calcium, in turn, can activate additional signaling molecules including calcineurin (CN) (18). In the heart, Gq-dependent signaling cascades are potent activators of CN, and Gq-dependent CN activation promotes cardiac hypertrophy (19, 20) through mechanisms that involve, at least in part, CN-dependent upregulation of TRPC6 (21). In the kidney, CN regulates the stability of the podocyte cytoskeletal protein synaptopodin (SYN) (22) and promotes a decrease in the number of podocytes by mechanisms that are dependent on gene transcription and podocyte apoptosis (23, 24). Moreover, recent studies are consistent with the notion that Gq-dependent CN activation and, in turn, TRPC6 induction are relevant to podocyte biology in vivo (25–27).

To investigate the role of Gq signaling in the pathogenesis of glomerular diseases, we expressed a constitutively active Gqα subunit (GqQ209L, herein referred to as GqQ>L) specifically in podocytes in a doxycycline-inducible (DOX-inducible) fashion (28). As previously reported, induction of GqQ>L does not cause glomerular injury (28), suggesting that a “second hit” may be required to induce podocyte injury, as has been suggested for...
Table 1. Effect of PAN nephropathy on glomerular structure

<table>
<thead>
<tr>
<th></th>
<th>Podocytes per glomerular profile</th>
<th>V/glom (×10^5/μm^3)</th>
<th>Nv(P/glom) (×10^7/μm^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated controls (n = 11)</td>
<td>8.74 ± 0.19</td>
<td>2.34 ± 0.14</td>
<td>56.8 ± 1.7</td>
</tr>
<tr>
<td>PAN controls (n = 9)</td>
<td>8.70 ± 0.19</td>
<td>2.82 ± 0.02</td>
<td>49.7 ± 2.2</td>
</tr>
<tr>
<td>PAN GqQ&gt;L (n = 13)</td>
<td>6.91 ± 0.6a</td>
<td>2.73 ± 0.15</td>
<td>42.4 ± 3.7b</td>
</tr>
</tbody>
</table>

*P < 0.05 versus controls and PAN controls; *P < 0.01 versus untreated controls. V/glom, glomerular volume; Nv(P/glom), podocyte density.

some familial forms of FSGS (29) such as activating mutations in TRPC6 (30). We therefore determined whether Gq activation in podocytes exacerbated glomerular injury in nephrosis induced by the podocyte toxin puromycin aminonucleoside (PAN) (31). We found that treatment with PAN induced robust albuminuria, foot process (FP) effacement, a decrease in the number of glomerular podocytes, and light microscopic features of FSGS in mice expressing GqQ>L specifically in podocytes compared with what was observed in control animals. These adverse effects were associated with both CN activation in vivo and enhanced expression of TRPC6. Deletion of Trpc6 prevented the development of FSGS and podocyte loss in this model. Similarly, CN blockade with FK506 reduced proteinuria and preserved podocyte numbers but had more modest effects on glomerular and tubular histology. These data support the notion that components of the Gq/TRPC6 signaling cascade are important therapeutic targets for the treatment of glomerular disease processes. Moreover, the data support the concept that a second hit may be required for the development of some familial forms of FSGS such as gain-of-function mutations in TRPC6.

Results

To evaluate the role of Gq-coupled signaling cascades in promoting podocyte injury, we expressed a constitutively active Gq subunit (GqQ>L) specifically in glomerular podocytes in a DOX-inducible fashion (28). As shown in Supplemental Figure 1A (supplemental material available online with this article; doi:10.1172/JCI76767DS1), this system requires 2 transgenic (Tg) animals (32). The first Tg animal expresses reverse tetracycline transactivator (rtTA) under the control of the human podocin promoter (NPHS2) to create NPHS2-rtTA mice (33). The second Tg mouse expresses GqQ>L under the control of tet operator sequence (tetO) and a minimal CMV promoter (PminCMV) to create tetO-GqQ>L mice (32). By breeding the 2 Tg mice, animals were obtained that expressed both transgenes. In these “double-Tg” mice (NPHS2-rtTA tetO-GqQ>L mice, herein referred to as GqQ>L mice), treatment with DOX induced transgene expression. For the studies, we used GqQ>L mice as well as their littermate controls (single-Tg and non-Tg animals), which do not express GqQ>L in the presence of DOX (28). At 3 to 4 months of age, the mice were treated with DOX for 1 week and then received 1 dose of PAN as previously described (34). The mice were then studied as discussed in the Methods.

As shown in Figure 1A and Supplemental Figure 1B, treatment with DOX and PAN induced robust albuminuria following induc-
To determine whether TRPC6 plays a role in podocyte injury, we generated GqQ>L mice lacking TRPC6. For these studies, controls, Trpc6+/+ GqQ>L mice, and Trpc6−/− GqQ>L mice (herein referred to as Trpc6-KO GqQ>L mice) were treated with DOX and PAN, as described in the Methods. As demonstrated in Figure 4A and Supplemental Figure 3A, PAN-induced albuminuria was significantly increased in Trpc6−/− GqQ>L mice compared with that seen in either baseline or wild-type (WT) controls treated with PAN. In Trpc6-KO GqQ>L mice, albuminuria induced by PAN was significantly decreased compared with Trpc6−/− GqQ>L mice treated with PAN. Moreover, the absence of TRPC6 completely prevented the development of FSGS in Trpc6-KO GqQ>L mice (Figure 4, B and D). Similarly, tubular injury (dilation and casts) was significantly attenuated in GqQ>L mice lacking TRPC6 compared with Trpc6−/− GqQ>L mice (Figure 4, C and E). Tubulointerstitial (TI) inflammation and fibrosis also tended to be decreased by KO of Trpc6, but these differences did not reach statistical significance (P = 0.07) (Supplemental Figure 3B). As shown in Figure 4F, these light microscopic findings were associated with a decrease in the number of glomerular podocytes associated with a decrease in the number of glomerular podocytes shown in Figure 4F, these light microscopic findings were asso -

Figure 1. Effect of GqQ>L induction on PAN nephrosis. (A) PAN caused a significant increase in albuminuria in mice expressing GqQ>L. There was significantly less albuminuria induced by PAN in control mice (CTRL) than in GqQ>L mice. (B and C) Treatment with PAN caused a significant increase in the percentage of mice that developed FSGS. Cystic structures were seen in a few glomeruli in GqQ>L mice (B, lower left panel), which likely indicates the accumulation of lipids or proteins in the cytoplasm of epithelial cells. Scale bars: 10 μm. (D) Treatment with PAN induced tubule dilation and casts in GqQ>L mice. Scale bars: 40 μm. (E) Podocyte numbers were significantly reduced by treatment with PAN in GqQ>L mice compared with numbers in both control mice treated with PAN and untreated control mice. (F and G) Treatment with PAN caused a significant decrease in both SYN and WTI expression in GqQ>L mice. For albuminuria and the histo-

Quantitative RT-PCR (qRT-PCR) was used to investigate the effect of GqQ>L induction on the CN-responsive genes Trpc6, regulator of CN 1 (Rcan1), and cyclooxygenase 2 (Cox2) (21, 28). As shown in Figure 4I, Cox2 mRNA was significantly increased in GqQ>L mice treated with PAN compared with levels in controls. Similarly, both Trpc6 and Rcan1 tended to be increased in GqQ>L mice compared with controls (Figure 4, I and J). KO of Trpc6 significantly reduced expression of Cox2 mRNA in GqQ>L mice. Similarly, Rcan1 tended to be decreased in Trpc6-KO mice compared with Trpc6−/− GqQ>L mice. A signal for Rcan1 was not detected in GqQ>L mice treated with PAN and untreated control mice. (H) Expression of the other TRPC family members Trpc3 and Trpc5. As shown in Supplemental Figure 5, Trpc3 mRNA levels tended to be increased in Trpc6−/− GqQ>L mice treated with PAN, similar to that seen in to mice treated with angiotensin II (AII) (37). In contrast, Trpc3 mRNA levels were significantly decreased in Trpc6−/− GqQ>L mice compared with those in Trpc6−/− GqQ>L mice. Given that KO of Trpc6 may have decreased cytosolic calcium levels, these observations could be consistent with the known stimulatory effects of calcium signal-
The effects of GqQ>L on glomerular ultrastructure in Trpc6<sup>−/−</sup> GqQ>L and Trpc6<sup>−/−</sup>-KO GqQ>L mice are shown in Figure 5A and B. FP effacement was observed in all experimental groups treated with PAN and was qualitatively more severe in Trpc6<sup>−/−</sup> GqQ>L mice (Figure 5A). Consistent with the qualitative impression, the frequency of filtration slits was significantly decreased in Trpc6<sup>−/−</sup> GqQ>L mice compared with the frequency in either WT controls or Trpc6<sup>−/−</sup>-KO GqQ>L mice (Figure 5B). In Trpc6<sup>−/−</sup> GqQ>L mice, the glomerular ultrastructure was markedly abnormal, with amorphous material in the capillary loops, focal capsular adhesions, and widespread degenerative changes in the podocytes and capillary loop endothelial cells. Microvillous changes were observed in a few of the Trpc6<sup>−/−</sup> GqQ>L and Trpc6<sup>−/−</sup>-KO GqQ>L mice.

KO of Trpc6 may reduce kidney injury by attenuating Gq-mediated increases in intracellular calcium and, in turn, decreasing enzymatic activity of the calcium-activated phosphatase CN. We therefore determined whether the CN inhibitor FK506 reduced glomerular injury in the GqQ>L mice treated with PAN. For these studies, the GqQ>L transgene was induced by DOX for 1 week, and then mice received 1 dose of PAN, followed by daily injections of either the CN inhibitor FK506 or vehicle, as described in the Methods. As shown in Figure 6A and Supplemental Figure 6A, FK506 reduced albuminuria in GqQ>L mice compared with that observed in vehicle-treated GqQ>L mice. FK506 had more modest and nonsignificant effects on the development of FSGS (Figure 6, B and C) and T1 inflammation and fibrosis (Supplemental Figure 6B), although there was a significant reduction in tubule injury (Figure 6, D and E). The beneficial effects of CN blockade were associated with a significant increase in podocyte density (Table 3) and preservation of SYN protein levels (Figure 6, F and G), without significantly affecting podocyte numbers (Figure 6H). As shown in Supplemental Figure 4B, Syn mRNA levels tended to be increased in both vehicle- and FK506-treated GqQ>L mice compared with those in controls. We were unable to detect a significant effect of WT1 levels by immunoblotting. As shown in Figure 6I, FK506 tended to reduce expression of the CN-responsive genes Trpc6 and Rcan1. In contrast, the increase in Cox2 mRNA caused by induction of GqQ>L (Figure 4I) was not affected by FK506 (Figure 6J) as previously reported (28).

The renin-angiotensin system has been suggested to be a disease accelerator in rodent models of diabetic kidney disease (39, 40). In support of this hypothesis, overexpression of a renin transgene was found to promote the development of advanced diabetic kidney disease in Tg rats (39). The enzyme renin initiates an endocrine cascade that results in the generation of the effector peptide AII and in turn activates the Gq-coupled AT1 receptor (39). Thus, Gq-coupled signaling cascades may provide the second hit that augments kidney damage in rodent models of diabetes. To determine whether the adverse effects of podocyte Gq activation are generalizable to other glomerular disease processes, we determined whether induction of GqQ>L exacerbated diabetic kidney disease in a mouse model of type 1 diabetes (FVB/N) Akita mice (41). As shown in Figure 7A, podocyte-specific expression of GqQ>L enhanced albuminuria in Akita mice (Gq Akita mice) at 16 and 20 weeks of age. Enhanced albuminuria was associated with a significant increase in mesangial expansion (Figure 7, B and C) in either a diffuse (Figure 7B, middle panel) or nodular (Figure 7B, right panel) pattern. The glomerular ultrastructure is shown in Figure 7D. Nodular thickening of the glomerular basement membrane (GBM) was seen on the subepithelial surface in Gq Akita mice, which was associated with a significant increase in average GBM width compared with that seen in age- and sex-matched nondiabetic control group mice (Figure 7E). Focal areas of FP flattening were also observed, which was qualitatively more severe in the diabetic mice (Figure 7D and Supplemental Figure 7).

### Table 2. Effect of Trpc6 KO on glomerular structure

<table>
<thead>
<tr>
<th>Condition</th>
<th>Podocytes per glomerular profile</th>
<th>V/glom (×10&lt;sup&gt;10&lt;/sup&gt; μm&lt;sup&gt;2&lt;/sup&gt;)</th>
<th>Nv/P/glom (×10&lt;sup&gt;−1&lt;/sup&gt;/μm&lt;sup&gt;3&lt;/sup&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAN controls</td>
<td>8.29 ± 0.17</td>
<td>2.59 ± 0.08</td>
<td>48.7 ± 0.7</td>
</tr>
<tr>
<td>PAN GqQ&gt;L</td>
<td>6.90 ± 0.33&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.47 ± 0.21</td>
<td>43.2 ± 15&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>PAN Trpc6 KO</td>
<td>7.67 ± 0.36</td>
<td>2.46 ± 0.22</td>
<td>47.8 ± 1.4</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < 0.05 versus PAN controls; <sup>b</sup>P < 0.05 versus PAN controls or PAN Trpc6-KO.

### Table 3. Effect of FK506 on glomerular structure

<table>
<thead>
<tr>
<th>Condition</th>
<th>Podocytes per glomerular profile</th>
<th>V/glom (×10&lt;sup&gt;10&lt;/sup&gt; μm&lt;sup&gt;2&lt;/sup&gt;)</th>
<th>Nv/P/glom (×10&lt;sup&gt;−1&lt;/sup&gt;/μm&lt;sup&gt;3&lt;/sup&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated controls</td>
<td>8.52 ± 0.17</td>
<td>2.46 ± 0.09</td>
<td>52.9 ± 0.5&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>PAN vehicle</td>
<td>6.67 ± 0.42&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.44 ± 0.24</td>
<td>31.0 ± 6.2</td>
</tr>
<tr>
<td>PAN FK506</td>
<td>7.18 ± 0.35</td>
<td>1.90 ± 0.23</td>
<td>48.4 ± 2.3&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < 0.05 versus untreated controls; <sup>c</sup>P < 0.01 versus GqQ>L mice treated with PAN and vehicle.
Discussion

In the present studies, we found that podocyte-specific activation of Gq in PAN nephrosis promoted albuminuria, reduced the number of glomerular podocytes, and induced FSGS. KO of Trpc6 both inhibited podocyte loss and completely prevented FSGS induced by PAN nephrosis in GqQ>L mice. These data suggest that TRPC6 is a key downstream target activated by Gq signaling that promotes podocyte injury. Intriguingly, glomerular damage induced by Gq required a second hit (ref. 28 and Supplemental Figure 2). Indeed, a second hit may be required for the development of glomerular disease in some familial forms of FSGS (29). In this regard, the age at diagnosis is quite broad in patients with FSGS caused by gain-of-function mutations in TRPC6 (15, 16, 42), consistent with the idea that some type of environmental or genetic second hit may be required for the development of glomerular disease in some familial forms of FSGS (29). In this regard, the age at diagnosis is quite broad in patients with FSGS caused by gain-of-function mutations in TRPC6 (15, 16, 42), consistent with the idea that some type of environmental or genetic second hit may be required for the development of glomerular disease (30). In support of this possibility, Gigante et al. (43) described TRPC6 mutations in patients with early-onset nephrotic syndrome. In 2 patients, TRPC6 mutations resulted in an amino acid (N125S) change that had previously been reported to cause the autosomal recessive disease congenital nephropathy of the Finnish type. Thus, the mutant NPHS1 allele may have accelerated disease in the pediatric patients with the TRPC6 (N125S) mutation. The concept of a second hit promoting disease progression is further supported by a recent study of autosomal recessive steroid-resistant nephrotic syndrome due to mutations in the NPHS2 gene encoding podocin (44). In this study, the authors suggested that the pathogenicity of 1 NPHS2 allele (R229Q) was dependent on a transassociated mutation in the other allele that caused a different amino acid change, consistent with the idea that a genetic second hit was required to develop a disease phenotype.

In the present study, Gq-dependent TRPC6 activation did not cause glomerular damage in the absence of an additional cell stressor. In this regard, PAN stimulates ROS generation in podocytes (45), and ROS potently activate TRPC6 (46, 47). Moreover, Gq-coupled GPCRs stimulate TRPC6 activation, both directly through the second messengers DAG and possibly IP3 (1), as well as indirectly by stimulating ROS generation (48). In this scenario, TRPC6 may serve as a final common pathway causing podocyte injury by several injury-promoting signaling cascades. These data suggest that, while we often study mediators of glomerular damage as individual entities, it is likely that the biological outcome represents the net effect of the number of injury-promoting pathways activated, the magnitude of activation of each individual mediator, and the genetic predisposition of the individual. Thus, treatment strategies that are currently used for idiopathic forms of FSGS may have beneficial effects in genetic forms of the disease by limiting the number of injury-promoting pathways that contribute to disease progression.

Current treatments for proteinuric kidney diseases include the use of therapies targeting the renin-angiotensin system. Given that these agents inhibit activation of the Gq-coupled AT1 receptor (1), the beneficial effects of the renin-angiotensin sys-

Table 4. Effect of GqQ>L on glomerular structure in Akita mice

<table>
<thead>
<tr>
<th></th>
<th>Podocytes per glomerular profile</th>
<th>V/glom (×10^3 μm^3)</th>
<th>Nv(P/glom) (×10^-5 μm^3)</th>
<th>Podocytes per glomerulus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nondiabetic controls (n = 6)</td>
<td>8.76 ± 0.27</td>
<td>2.57 ± 0.09</td>
<td>56.8 ± 1.7</td>
<td>144 ± 4.5</td>
</tr>
<tr>
<td>WT Akita (n = 9)</td>
<td>8.35 ± 0.28</td>
<td>3.61 ± 0.17^a</td>
<td>38.3 ± 1.3^a</td>
<td>135 ± 3.5</td>
</tr>
<tr>
<td>Gq Akita (n = 8)</td>
<td>8.47 ± 0.23</td>
<td>3.56 ± 0.26^a</td>
<td>39.4 ± 0.9^a</td>
<td>136 ± 3.4</td>
</tr>
</tbody>
</table>

^aP < 0.01 or ^bP < 0.001 versus nondiabetic controls.
term blockade in glomerular diseases may be mediated at least in part by inhibition of Gq signaling. In support of this hypothesis, multiple Gq-coupled GPCRs contribute to kidney injury in animal models of glomerular disease including receptors for ETA, TP, platelet-activating factor (PAF), cysteinyl leukotrienes, and EP1 (1, 5). Moreover, combined use of AT1 and ETA blockers is a promising treatment for glomerular diseases (10–12). An alternative treatment strategy might be to target a final common pathway activated by each of these receptor systems such as Gq (1). YM254890 is a specific Gq inhibitor that has been tested in experimental animals (49–51). In these studies, YM254890 reduced systemic BP and inhibited platelet aggregation without apparent adverse effects. While additional studies will be required to determine the effects of YM254890 in proteinuric kidney diseases, the current studies suggest that this class of agents may have beneficial actions in glomerular disease processes, which might be useful for the treatment of kidney diseases in humans.

Other therapeutic strategies include targeting downstream signaling cascades linked to Gq activation. TRPC6 is stimulated by Gq through generation of the second messenger DAG and possibly IP3 (1). These signaling molecules are products of PLC following activation of either Gq-coupled GPCRs or RTKs (52), and both these receptor systems play key roles in glomerular disease processes (1, 53). Activation of TRPC6 increases cytosolic calcium levels and stimulates Rho A (3, 4). Moreover, Gq-coupled signaling cascades activate other TRPC family members including TRPC5 (54), which further enhances intracellular calcium levels and promotes RAC1 activation (3, 4). Both Rho A and RAC1 modulate cytoskeletal dynamics and play critical roles in regulating glomerular filtration barrier integrity (3, 55–59). Gq signaling also stimulates CN (26, 60) and causes a decrease in glomerular podocytes by mechanisms that are dependent on gene transcription (23, 24). In this regard, Gq-dependent CN activation induced TRPC6 expression (21) without affecting Trpc5 mRNA levels (Supplemental Figure 5). This increase in TRPC6 expression causes additional increases in intracellular calcium levels and augments Rho A activation (3, 4). Thus, Gq signaling stimulates multiple signaling cascades (Rho GTPases and CN) that might be targeted to promote podocyte survival and glomerular filtration barrier integrity.

Another therapeutic strategy is CN inhibition (29). Pharmacological CN inhibitors are frequently used for the treatment of primary glomerular disease processes (29, 61). While the beneficial effects of these agents have been attributed to their immunological actions (62), accumulating evidence suggests that this calcium-activated phosphatase has important nonimmunological effects in glomerular diseases, including promoting degradation of the podocyte cytoskeletal protein SYN (22, 62), as well as inducing podocyte apoptosis and podocyte loss (23, 24). In the present studies, GqQ>L induction both activated CN and upregulated TRPC6 in a CN-dependent fashion. These observations may be relevant to kidney pathophysiology, because TRPC6 is induced in several primary glomerular diseases (17). We therefore determined whether the CN inhibitor FK506 attenuated glomerular injury induced by PAN in GqQ>L mice. We found that FK506 attenuated both albuminuria and tubular injury induced by GqQ>L in PAN nephrosis as well as enhanced expression of SYN. Despite these beneficial effects, FK506 had little effect on glomerular histology. The dissociation between effects on proteinuria and renal injury is consistent with several clinical studies suggesting that treatments that inhibit proteinuria do not necessarily translate into reduced disease progression (11, 63). Our findings of the inability of CN inhibition to improve renal histology should, however, be tempered by the observation that current pharmacological CN inhibitors have important off-target effects (64). For example, CN inhibitor therapy has been linked to the development of FSGS in some patients, perhaps by promoting renal ischemia (29, 65). In support of this hypothesis, glomerular volume was reduced in GqQ>L mice treated with FK506 (Table 3), consistent with the idea that FK506 caused renal ischemia and, in turn, a reduction in glomerular volume (66). Moreover, FK506 had little effect on GqQ>L-dependent induction of COX2 (Figure 6J). Indeed, in previous studies, we found that FK506-induced expres-
sion of Cox2 mRNA (28) and enhanced generation of COX2 metabolites may contribute to CN inhibitor toxicity (65). The development, however, of more specific CN inhibitors with fewer off-target effects may provide the benefits of CN blockade with a more favorable side-effect profile (67, 68). In future studies, it will therefore be of interest to test the effects of these more specific CN inhibitors in glomerular disease processes.

Although FK506 did not affect glomerular pathology, tubule dilation and casts were reduced by KO of Trpc6. Scale bars: 40 μm. (B) Treatment with PAN reduced podocyte numbers in Trpc6+/GqQ>L mice. Podocyte numbers in Trpc6-KO mice were similar to those in WT controls. (G and H) KO of Trpc6 preserved expression of SYN and WT1 in GqQ>L mice. (I and J) Cox2 mRNA was increased in Trpc6+/GqQ>L mice, and this increase was prevented by KO of Trpc6. A similar pattern was observed for Rcan1 and Trpc6 mRNA levels. The albuminuria experiments were performed in 15 WT controls, 20 Trpc6+/GqQ>L mice, and 26 Trpc6-KO GqQ>L mice. For the histology studies, 8 WT controls, 22 Trpc6+/GqQ>L mice, and 16 Trpc6-KO GqQ>L mice were used. For immunoblotting experiments, 4 controls, 4 Trpc6+/GqQ>L mice, and 10 Trpc6-KO GqQ>L mice were used. For qRT-PCR, mRNA samples from 12 WT controls, 17 Trpc6+/GqQ>L mice, and 10 Trpc6-KO GqQ>L mice were used. *P < 0.05, †P < 0.01, or ‡P < 0.005 versus the indicated groups using a χ2 analysis for histologic data and ANOVA, followed by Bonferroni's post-hoc analysis, for the other studies. KO GqQ>L, Trpc6-KO GqQ>L mice; WT GqQ>L, Trpc6+/GqQ>L mice; GqQ>L-WT, WT GqQ>L mice.

Figure 4. Effect of Trpc6-KO on PAN nephrosis. (A) Albuminuria was increased in Trpc6+/GqQ>L mice. KO of Trpc6 attenuated the increase in albuminuria. (B and D) FSGS was increased in Trpc6+/GqQ>L mice. KO of Trpc6 prevented the development of FSGS. Scale bars: 10 μm. (C and E) Tubule dilation and casts were reduced by KO of Trpc6. Scale bars: 40 μm. (F) Treatment with PAN reduced podocyte numbers in Trpc6+/GqQ>L mice. Podocyte numbers in Trpc6-KO mice were similar to those in WT controls. (G and H) KO of Trpc6 preserved expression of SYN and WT1 in GqQ>L mice. (I and J) Cox2 mRNA was increased in Trpc6+/GqQ>L mice, and this increase was prevented by KO of Trpc6. A similar pattern was observed for Rcan1 and Trpc6 mRNA levels. The albuminuria experiments were performed in 15 WT controls, 20 Trpc6+/GqQ>L mice, and 26 Trpc6-KO GqQ>L mice. For the histology studies, 8 WT controls, 22 Trpc6+/GqQ>L mice, and 16 Trpc6-KO GqQ>L mice were used. For immunoblotting experiments, 4 controls, 4 Trpc6+/GqQ>L mice, and 10 Trpc6-KO GqQ>L mice were used. For qRT-PCR, mRNA samples from 12 WT controls, 17 Trpc6+/GqQ>L mice, and 10 Trpc6-KO GqQ>L mice were used. *P < 0.05, †P < 0.01, or ‡P < 0.005 versus the indicated groups using a χ2 analysis for histologic data and ANOVA, followed by Bonferroni's post-hoc analysis, for the other studies. KO GqQ>L, Trpc6-KO GqQ>L mice; WT GqQ>L, Trpc6+/GqQ>L mice; GqQ>L-WT, WT GqQ>L mice.
that augments kidney damage in diabetic kidney disease. In support of this hypothesis, induction of GqQ>l promoted albuminuria, enhanced mesangial expansion, and increased GBM width in Gq Akita mice compared with WT Akita animals. In WT Akita mice, the diabetic milieu was also associated with a significant increase in expression of mRNA for the CN-responsive genes Trpc6 (P < 0.05) and Rcan1 (P < 0.01), consistent with published studies suggesting that renal CN activity is enhanced in rodent models of diabetes (23, 73). Surprisingly, induction of GqQ>l was not associated with a significant increase in mRNA for either Trpc6 or Rcan1. We speculate that these observations are the result of compensatory mechanisms that limit the duration of Gq activation, including enhanced expression of the negative regulator of Gq signaling RGS2 (regulation of G protein signaling 2) (74) and modulation of IP3 receptor expression and activity (75, 76). In support of this hypothesis, IP3 receptor expression tended to be decreased in both groups of Akita mice compared with that in controls, and RGS2 levels tended to be higher in Gq Akita mice compared with those in WT Akita mice (Supplemental Figure 10). Regulation of Gq-dependent calcium signaling is, however, complex and includes not only modulation of mRNA and protein levels of the downstream signaling molecules, but also posttranslational modifications, accessory proteins, and proteasomal degradation (74–77). These regulatory mechanisms are an ongoing and evolving area of investigation, as they are incompletely understood. Further study will be required to better understand these counterregulatory pathways.

In the present study, systemic BP was similar in Trpc6+/+ GqQ>l and Trpc6-KO GqQ>l mice. This finding contrasts with the higher systemic BP reported by Dietrich et al. (78) in the initial description of Trpc6-KO mice. While we can only speculate on the reason for this difference, genetic background may play a role. In the study by Dietrich et al. (78), the mice were on a mixed 129Sv/C56BL/6J background; in the present study, the mice were on an inbred FVB/NJ background. Consistent with an effect of genetic background on the BP phenotype, Eckel et al. (37) reported no differences in systemic BP by either tail-cuff manometry or radiotelemetry in mice on an inbred 129SvEv background. Moreover, a significant increase in systemic BP would likely have minimized the beneficial effects of Trpc6-KO in the PAN nephrosis model, given the adverse effect of increased BP on the progression of kidney disease.

Finally, glomerular disease in mice is generally less severe compared with glomerular disease processes in other rodent models (45). Thus, the lack of a phenotype in GqQ>l mice might not be generalizable to other species. In addition, the adverse effects of Gq activation in the present study are likely cell-type specific. With regard to the latter, P2Y2 purinergic receptors are potent activators of TRPC6 in podocytes (46, 79), but whole-body KO of the gene encoding the P2Y2 receptor was found to aggravate kidney injury following subtotal nephrectomy (80). In that study, the authors attributed the adverse effects of P2Y2 KO to higher systemic BP and ineffective compensatory hypertension (80). Indeed, the P2Y2 receptor has complex effects on salt and water metabolism (81).
upregulated TRPC6 expression in a CN-dependent fashion. KO of Trpc6 ameliorated albuminuria, FP effacement, and the decrease in glomerular podocyte numbers as well as prevented the development of FSGS and inhibited tubular injury. CN inhibition had similar beneficial effects on albuminuria, but was less effective in reducing renal histologic damage. Taken together, these data suggest that components of the Gq/CN/TRPC6 signaling cascade are important therapeutic targets for the treatment of FSGS and likely other glomerular disease processes. In support of the latter, that caused a significant increase in systolic BP following subtotal nephrectomy compared with that in WT animals (80). Additional studies will therefore be required to determine whether targeting Gq signaling using pharmacologic agents is a potentially beneficial strategy for treating glomerular disease processes. In summary, we found that induction of GqQ>L specifically in podocytes caused robust albuminuria, FP effacement, decreased numbers of glomerular podocytes, and light microscopic features of FSGS. Moreover, Gq activation stimulated CN activity and

Figure 6. Effect of CN inhibition on PAN nephrosis in GqQ>L mice. (A) FK506 inhibited albuminuria induced by PAN in GqQ>L mice. (B and C) The development of FSGS was similar in GqQ>L mice treated with either vehicle or FK506. Scale bars: 10 μm. (D and E) FK506 significantly inhibited tubule dilation and casts. Scale bars: 40 μm. (F and G) FK506 significantly preserved SYN expression. (H) PAN nephrosis significantly reduced podocyte numbers in GqQ>L mice treated with vehicle compared with those in an untreated non-Tg control group. FK506 caused a modest and nonsignificant increase in podocyte numbers. (I) FK506 tended to reduce expression of the CN-responsive genes Trpc6 and Rcan1. (J) The increase in Cox2 mRNA caused by induction of GqQ>L (Figure 4I) was not affected by FK506. For the albuminuria studies, 16 vehicle-treated mice and 21 mice treated with FK506 were used. Sixteen vehicle-treated mice and 8 mice treated with FK506 were used for the histologic studies. For the immunoblot studies, 4 vehicle-treated mice and 4 mice treated with FK506 were used. To assess podocyte numbers, 11 untreated controls, 13 GqQ>L mice treated with vehicle, and 8 GqQ>L mice treated with FK506 were used. For qRT-PCR, mRNA samples from 14 vehicle-treated mice and 7 mice treated with FK506 were used. *P < 0.05, †P < 0.025, or ‡P < 0.01 versus the indicated groups using Fisher’s exact test for histologic data, a 2-tailed t test for albuminuria and immunoblotting data, and ANOVA, followed by Bonferroni’s post-hoc analysis, for the other studies.
the adverse effects of podocyte Gq activation were generalizable to diabetic kidney disease in a mouse model of type 1 diabetes. Moreover, the data support the concept that a second hit may be required for the development of some familial forms of FSGS such as gain-of-function mutations in TRPC6.

Methods

Materials. PAN was obtained from Sigma-Aldrich. Injectable FK506 (Astellas Pharma) was obtained from the Duke University Medical Center Pharmacy. The tetO-GqQ>L Tg mice were created as previously described (28). Podocin promoter rtTA Tg mice were originally obtained from Jeffery Kopp (33) at the NIH and are now available through The Jackson Laboratory. Trpc6-KO mice were obtained from Lutz Birnbaumer (78) through a collaboration with Michelle Winn.

Experimental protocol. All experiments were performed using mice backcrossed onto an FVB/NJ background for more than 10 generations. In pilot studies, age- and sex-matched 3- to 4-month-old littermates received DOX in their drinking water (with 2% sucrose to enhance palatability) for 1 week, and then nephrosis was induced by a single i.p. injection of PAN (500 mg/kg) as previously described (34). DOX was continued for the next 2 weeks, and urine was collected on the day prior to the PAN injection (day 0) and on days 7, 10, 14, and 28.
after injection. As shown in Supplemental Figure 11, these pilot studies suggested that the most robust albuminuria occurred 10 days after PAN injection in GqQ>L mice. For the FSGS studies, we therefore collected urine on days 0 and 10. Mice were sacrificed and their kidneys harvested for examination by light microscopy, transmission electron microscopy (TEM), and fluorescence microscopy and for preparation of enriched glomerular preparations as previously described (28).

To determine the role of TRPC6 in PAN nephropathy, Trpc6−/− mice (Trpc6−/− mice) were bred onto an FVB background for more than 10 generations and then crossed with tetO-rtTA and Nphs2 GqQ>L mice. Heterozygous offspring were then bred to create both double-Tg mice lacking Trpc6 as well as controls (single-Tg and non-Tg Trpc6−/− mice). Mice were then studied using the PAN protocol described above.

To determine the role of CN in PAN nephropathy, GqQ>L mice were treated with an injectable form of FK506 by diluting the drug in saline (0.9% sodium chloride) and then administering twice-daily s.c. injections of either saline vehicle or 10 mg/kg/day FK506 beginning the day of PAN treatment and continuing until harvest. Mice were then studied using the PAN protocol described above.

For the NFAT reporter studies, Nphs2-rtTA mice and tetO-GqQ>L mice were bred with mice expressing an NFAT-responsive promoter driving expression of β-gal (36) to create mice with 2 different transgenes. Double-Tg offspring were then bred to create mice that expressed all 3 transgenes. In these triple-Tg mice, treatment with DOX induced GqQ>L and activated CN, which promoted expression of β-gal. Controls included double- and single-Tg mice (labeled “other Tg” mice) as well as non-Tg animals. To measure NFAT promoter activity, cortical and glomerular homogenates were prepared, and β-gal activity was measured using the Galacto-Star Chemiluminescent Reporter Gene Assay (Applied Biosystems). Data are expressed as β-gal activity per milligram protein.

To determine the effect of GqQ>L induction on TRPC6 expression in vivo, mice expressing GqQ>L and control mice were treated for 1 week with DOX in the drinking water, and then enriched glomerular preparations were prepared as previously described (28). The glomerular preparations were then either: (a) snap-frozen in liquid nitrogen and saved at −70°C for preparation of total cellular RNA; or (b) solubilized in NP-40 lysis buffer (50 mM Tris-HCl, 150 mM sodium chloride, 2 mM EDTA, 1% IGEPA L CA-630 [NP-40]) with protease inhibitors (Sigma-Aldrich) by sonication and then enriched glomerular preparations were used to either: (a) prepare total cellular RNA; or (b) solubilize in NP-40 lysis buffer and protein samples were then frozen at −70°C. By light microscopy, the purity of the glomerular preparations ranged from 60% to 70%.

Reverse transcription followed by qPCR. Total cellular RNA was prepared using glomerular preparations and TRizol reagent (Life Technologies) according to the manufacturer’s directions. RNA was treated with RNase-free DNase (QIAGEN) and then reverse transcribed with SuperScript Reverse Transcriptase (Invitrogen) and oligo (dT) primers. Real-time quantitative PCR was performed using an iCycler (Bio-Rad) and the universal SYBR Green PCR Master Mix Kit (Applied Biosystems, Life Technologies). The amplification signals were normalized to endogenous cyclophilin mRNA levels. The primer sequences used for qRT-PCR can be found in the Supplemental Methods.

Immunoblot analysis. Immunoblotting was performed as previously described (28) using the Invitrogen Bio-Tris mini-gel system and the following Abs: (a) a mouse mAb against SYN (catalog 65194; Progen Biotechnik); (b) a mouse mAb against WT1 (immunoblotting) (catalog sc-7385; Santa Cruz Biotechnology Inc.); and (c) a rabbit polyclonal Ab against TRPC6 (catalog ACC-017; Alomone Labs). As a positive control for the TRPC6 immunoblotting experiments, human embryonic kidney cells (HEK293 cells) were obtained from the Duke Cell Culture Facility and were transfected with a TRPC6 cDNA (83). HEK293 cell lysates were then prepared using NP-40 lysis buffer. To assess protein loading, the immunoblots were stripped according to the manufacturer’s instructions, and immunoblotting was performed using a mouse mAb against β-actin (catalog MAB1501R; Chemicon International). For densitometry, the immunoblots were converted into a digital format using an Epson Perfection 1670 Scanner (Seiko Epson) and then analyzed using ScanAnalysis 2.5 software (Biosoft). Densitometric data were normalized by dividing the protein signals for TRPC6, SYN, or WT1 by the matched signal for β-actin. When multiple blots were required to analyze a large number of samples, all gels were run and transferred simultaneously to PVDF membranes. The proteins were then detected by immunoblotting using the Abs described above. For these studies, ECL (Thermo Scientific) was performed by placing all PDVF membranes into a film cassette and exposing the x-ray film to all immunoblots for the same duration. The full, uncut gels are shown in the supplemental material.

IHC. Mouse kidney cortex was embedded in OCT compound, snap-frozen in liquid nitrogen, and stored at −70°C until sectioning. Expression of SYN and WT1 was identified by indirect immunofluorescence using a mouse mAb against SYN (catalog 65194; Progen Biotechnik), a rabbit polyclonal Ab against WT1 (catalog sc-192; Santa Cruz Biotechnology Inc.), or a rat mAb (clone 3F10) against the HA tag in the GqQ>L construct (catalog 11-867-423-001; F. Hoffmann-La Roche). Briefly, frozen sections were fixed in 2% paraformaldehyde for 10 minutes, air dried, treated for 10 minutes with 1% Triton-X in Dulbecco’s...
PBS (D-PBS), and then blocked for 1 hour in 20 mM Tris-HCl, 157 mM NaCl, pH 7.6 (TBS), with 0.2% Tween-20 (T-TBS) and 5% nonfat dry milk. The SYN, WT1, and HA Abs were added at a dilution of 1:200 in T-TBS with 5% nonfat dry milk. After incubating overnight, slides were washed 3 times in D-PBS and then incubated for 1 hour with either an Alexa Fluor 488 donkey anti-rabbit Ab (catalog A21206; Life Technologies), a goat CY3 anti-rat Ab (catalog A1052; Life Technologies), a rhodamine-labeled goat anti-mouse Ab (catalog R6393; Life Technologies), or a fluoresceinated donkey anti-mouse Ab (catalog ab98554; Abcam), all at a dilution of 1:1,000 in T-TBS with 5% nonfat dry milk. Slides were then washed 3 times in D-PBS, coverslips were applied using adhesive containing DAPI, and slides were examined using a Nikon Eclipse TE2000-S fluorescence microscope.

**BP measurements.** Systolic BP was measured using a computerized tail-cuff system (Hatteras Instruments) in conscious mice as previously described (34). This technique has previously been shown to correlate closely with intra-arterial measurements (84).

**Histopathology.** Light microscopic sections were stained with H&E and periodic acid Schiff (PAS) and then evaluated by a pathologist (A.F. Buckley) blinded to the genotype. FSGS, tubule dilation and casts, and TN inflammation and fibrosis were graded using a semiquantitative scale of 0 to 3 (0 = normal, 1 = mild, 2 = moderate, 3 = severe). For the Akita studies, mesangial expansion was assessed using the same grading scale as that described previously (41).

**Albuminuria.** Urine was collected for 24 hours in metabolic cages specifically designed for collection of urine in mice (Hatteras Instruments). Urinary albumin concentrations were measured using a kit from AssayPro, and urinary creatinine levels were measured using a kit from Exocell. Urinary albumin excretion was expressed as both the number of mice with the specified histologic abnormality. P values of less than 0.05 were considered significant. Graphs of the histologic findings are presented as the percentage of mice with the specified abnormality to permit a more effective comparison of the differences between the experimental manipulations in studies with an imbalance in the number of mice in each group.

**Study approval.** All animal care and experiments conformed to NIH guidelines (Guide for the Care and Use of Laboratory Animals. 8th ed. The National Academies Press. 2011.) and were approved by the IACUC of the Duke University Medical Center.

**Acknowledgments**

These studies were supported by grants from the NIH (RO1-DK075688 and R01-DK087707, to R.F. Spurney); the Veterans Administration Merit Review Program (BX000791, to R.F. Spurney); and by a Department of Medicine Integrated Research Award through an internal grant program at Duke University Medical Center (to P.B. Rosenberg and R.F. Spurney). We thank Natalie Mattocks and William Eisner for their technical assistance with the studies.

Address correspondence to: Robert F. Spurney, MSRB II, Room 2013, 106 Research Drive, Durham, North Carolina 27710, USA. Phone: 919.684.9729; E-mail: robert.spurney@dm.duke.edu.


